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The brain systems underlying placebo analgesia are insufﬁciently understood. Here we
performed a systematic, participant-level meta-analysis of experimental functional neuroimaging studies of evoked pain under stimulus-intensity-matched placebo and control conditions, encompassing 603 healthy participants from 20 (out of 28 eligible) studies. We ﬁnd
that placebo vs. control treatments induce small, widespread reductions in pain-related
activity, particularly in regions belonging to ventral attention (including mid-insula) and
somatomotor networks (including posterior insula). Behavioral placebo analgesia correlates
with reduced pain-related activity in these networks and the thalamus, habenula, mid-cingulate, and supplementary motor area. Placebo-associated activity increases occur mainly in
frontoparietal regions, with high between-study heterogeneity. We conclude that placebo
treatments affect pain-related activity in multiple brain areas, which may reﬂect changes in
nociception and/or other affective and decision-making processes surrounding pain.
Between-study heterogeneity suggests that placebo analgesia is a multi-faceted phenomenon
involving multiple cerebral mechanisms that differ across studies.
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P

lacebo effects contribute substantially to treatment outcomes in both medical research and clinical practice. A
better understanding of the underlying mechanisms is thus
important for optimizing drug development and clinical care1.
Placebo analgesia is the most robust and best-studied type of
placebo effect1–3. A growing number of neuroimaging studies
elucidate the brain correlates of placebo analgesia. These studies,
and meta-analyses of their ﬁndings, have provided evidence for
the involvement of brain regions linked to nociceptive processing,
including early pain-gating mechanisms, but also to decisionmaking, cognitive appraisal, reward/motivation, emotional regulation4–7, and other forms of learning and social cognition8
relevant for health behaviors.
Nevertheless, the results of these studies vary substantially4, and
the lack of large-sample assessments hampers the detection of small
to moderate effects9 and makes it difﬁcult to identify precisely
which structures are consistently altered by placebo treatment.
Previous meta-analyses have all relied on published coordinates of
activation peaks. These incomplete summaries of the full activation
maps provide only approximate information on replicability across
studies and are susceptible to bias10. These limitations can be
overcome by meta-analyses based on single-participant, wholebrain images, which are sometimes referred to as ‘mega-analyses’11.
As meta-analyses on participant-level data are preferable in terms of
statistical power and risk-of-bias11, a mega-analysis of placeboinduced brain activity can be expected to foster convergence in our
understanding of placebo analgesia, to provide novel insights into
the underlying neural mechanisms, and guide the development of
predictive methods of individual placebo analgesia from neuroimaging data, which would be of crucial importance both from a
clinical and drug development point of view. Here, we conducted a
systematic participant-level meta-analysis of 20 independent neuroimaging studies on experimental placebo analgesia. Based on
whole-brain activation patterns in a total of N = 603 healthy participants, we mapped the effects of placebo treatment on painrelated brain activity and identiﬁed neural correlates of individual
differences in behavioral placebo analgesia.
Results
Image quality. All included studies (N = 603 participants from
20 studies, see ref. 7 and Table 1) aimed at covering the whole
brain down to the mid-pons/superior cerebellar level. Image
alignment to MNI-space was satisfactory for all studies, but
coverage was often incomplete near the boundaries of the brain
(see Supplementary Figs. 2 and 3), particularly in the inferior
brainstem, cerebellum, and ventral prefrontal regions. These
partially missing data are likely due to between-study differences
in ﬁeld-of-view and/or signal dropout artifacts. For one study12,
only maps with white-matter regions masked out were available.
Outlier screening (see Supplementary Methods and Results)
indicated pain ratings that were too low for inclusion in six
participants (responses <5% of the pain scale). Problematic image
features were found in 12 (2.0%) participants. These include
imaging artifacts (six participants), extreme values (four participants), or likely errors in ﬁrst-level analysis (two participants).
These outlier participants were retained in our analysis (see
Supplementary Methods and Results, Supplementary Figs. 4, 5,
Supplementary Table 8 for an analysis excluding high risk-of-bias
studies and outlier participants, which shows similar results to the
full sample analysis in terms of effect sizes).
Voxel-wise results: pain stimulation effects. Painful stimulation
compared to baseline induced large peak effects (g > 0.8); with the
largest located in the insula, bilaterally (Fig. 1a, Supplementary
Fig. 6, Supplementary Table 9). In general, cerebral activations
2

and de-activations were found in regions typical for experimental
pain (compare: Fig. 1b and ref. 13). The τ-statistic indicated
considerable between-study heterogeneity in pain-related activity
throughout most of the brain (Supplementary Fig. 7), which was
expected given the large inter-study diversity regarding experimental pain-induction, image acquisition, and image processing
(Supplementary Tables 2–5).
Voxel-wise results: effect of placebo treatment. In general,
placebo treatment had a small (g < 0.2) effect on pain-related
brain activity, as compared to the matched control conditions
(Fig. 2a, b). Signiﬁcant placebo-associated decreases were found
in the right insula, near the habenula and the splenium of the
corpus callosum, and in the cerebellum (p < 0.05, FWER corrected with pTFCE; Fig. 2a light blue, Supplementary Fig. 8,
Supplementary Table 10). No areas showed placebo-related
increases at the FWER-corrected threshold treating study as a
random effect.
Estimated between-study heterogeneity in voxel-level effect
sizes was low in the signiﬁcantly de-activated regions (Fig. 2c,
Supplementary Fig. 8, Supplementary Table 10). However, many
regions of the brain showing sub-threshold placebo-related
increases showed statistically signiﬁcant τ-values, indicating
between-study heterogeneity in effects (Fig. 2c). These included
multiple prefrontal cortical areas, perigenual anterior cingulate
cortex, intraparietal sulcus, precuneus, basal ganglia, and the left
middle insula. A brain-wide correlation analysis indicated that
placebo treatment effects were positively and signiﬁcantly
correlated across brain regions with τ-values (r = 0.191, 95% CI
[0.187, 0.196], p < 0.001, Supplementary Fig. 9), indicating that
areas showing placebo-induced increases tended to have higher
levels of between-study heterogeneity. Thus, activation increases
varied more substantially across studies than activation decreases.
We therefore performed an exploratory ﬁxed-study-effects
analysis of placebo effects, which tests for effects within this set of
studies without the intent of generalizing to new, unobserved
studies. In addition to decreases reported above, this analysis
showed reduced activity in the middle cingulate cortex, the
bilateral supplementary motor area (SMA), left fusiform cortex
and cerebellum (Fig. 2d, light blue). The ﬁxed-effects analysis
revealed signiﬁcant placebo-induced activation in the anterior
intraparietal sulcus, precuneus, and dorsolateral prefrontal cortex
(DLPFC) (Fig. 2d gold, Supplementary Table 11).
To further follow up on potential sources of between-study
heterogeneity, we explored the possibility of explaining heterogeneity through study-level experimental features, such as the
method of placebo induction. A preliminary comparison of
placebo induction methods (conditioning and suggestions versus
suggestions only) showed no signiﬁcant differences in placeborelated brain activity after correction for multiple comparisons
(Supplementary Fig. 10).
Voxel-wise results: correlations with placebo analgesia. In the
vast majority of voxels (Fig. 3a), placebo analgesia was negatively
correlated with placebo-induced changes in brain activity. Thus,
the larger the activity decreases, the more analgesia a participant
reported (Fig. 3a, blue and light blue). Negative correlations were
strongest and statistically signiﬁcant in the bilateral thalamus,
right anterior, middle and posterior insula, right secondary
somatosensory cortex, right superior temporal gyrus, right cerebellum (around the dorsal part of lobule VI), basal ganglia, the
mid-cingulate cortex, as well as SMA/pre-SMA (p < 0.05, FWER
corrected with pTFCE; Fig. 3a light blue; also see Supplementary
Fig. 11, Supplementary Table 12). The activity of contralateral
(left) areas of the insula (z-score = 3.9, r = 0.17, p = 0.00005), the
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Table 1 Studies included in the meta-analysis.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20

First author

Year

n

Design

Mean age (y)

Sex (%
male)

Pain stimulus

Placebo
induction

Treatment

Atlas48
Bingel53
Bingel70
Choi54
Eippert56
Ellingsen71
Elsenbruch72
Freeman51
Geuter55
Kessner73
Kong49
Kong50
Lui74
Rütgen52
Schenk75
Theysohn76
Wager12,A
Wager12,B
Wrobel57
Zeidan43

2012
2006
2011
2011
2009
2013
2012
2015
2013
2013
2006
2009
2010
2015
2014
2014
2004
2004
2014
2015

21
19
22
15
40
28
36
24
40
39
10c
12a
31
102
32
30
24
23
38
17a

within
within
within
within
within
within
within
within
within
between
within
within
within
between
within
within
within
within
within
within

25
24
28
25
26
26
26
27
26
26
27
26
23
25
26
35
NA
NA
26
28

48
79
68
100
100
68
42
50
100
51
60
42
45
31
53
50
NA
NA
58
47

heat
laser
heat
electrical
heat
heat
distension
heat
heat
heat
heat
heat
laser
electrical
cap + heat
distension
electrical
heat
heat
heat

sug
sug + cond
sug + cond
sug + cond
sug + cond
sug
sug
sug + cond
sug + cond
cond
sug + cond
sug + cond
sug + cond
sug + cond
sug
sug
sug
sug + cond
sug + cond
sug + cond

IV-infusion
topical cream
IV-infusion
IV-infusion
topical cream
nasal spray
IV-infusion
topical cream
topical cream
topical cream
sham acupuncture
sham acupuncture
sham TENS
pill
topical cream
IV-infusion
topical cream
topical cream
topical cream
topical cream

A Sub-study 1, B Sub-study 2, between between-group design, cap, capsaicin, cond conditioning, IV intravenous, L left, NA not available, R right, sug suggestions, TENS transcutaneous electrical nerve
stimulation, within within-subject design.
aPlacebo-treatment groups, only.

Fig. 1 Pain-related activity in experimental placebo imaging studies. a Statistically signiﬁcant pain-responses (permutation test, controlled for FWER,
two-sided p < 0.05), and b whole-brain unthresholded standardized effect size g, of acute pain stimulation > baseline, pooled across placebo and control
conditions (FWER-corrected permutation test results are delineated as a back contour); range g: [−0.82, 1.68]; all: n = 543–603 individuals from 17 to 20
independent studies per voxel. Three-dimensional coronal slices are equidistantly distributed from y = 60 to −68 mm. Axial slices range equidistantly from
z = −22 to 42 mm. Custom coordinates for sagittal slices are displayed in mm. Source data (results as 3d-volumes) are provided at https://osf.io/n9mb3/.

secondary somatosensory cortex (z-score = 4.0, r = 0.21, p =
0.00003) was also negatively correlated with analgesia but was
only signiﬁcant without correcting for multiple comparisons
(Fig. 3a, blue).
Positive correlations between behavioral placebo analgesia and
brain activity, i.e. increasing brain activity with stronger placebo
response, did not reach statistical signiﬁcance (p < 0.05, FWER
corrected, pTFCE). Without correcting for multiple comparisons,
positive correlations (Fig. 3a, b, red) were observed near the
subgenual cingulate cortex (z-score = 1.8, r = 0.14, puncorr = 0.036),
in the orbitofrontal cortex (z-score = 2.7, r = −0.17, puncorr = 0.003),
and the prefrontal pole (z-score = 2.6, r = −0.13, puncorr = 0.005).
Levels of between-study heterogeneity were negligible in regions
showing signiﬁcant correlations between behavioral placebo

analgesia and brain activity (Fig. 3b, Supplementary Fig. 11,
Supplementary Table 12), suggesting that correlations were driven
by inter-individual differences rather than systematic differences
across studies. Across the brain, between-study heterogeneity did
not reach FWER signiﬁcance, but was largest in the basal ganglia,
orbitofrontal and dorsolateral prefrontal cortices; see Fig. 3c).
Between-study heterogeneity was not spatially associated with
correlations across voxels (Supplementary Fig. 12); thus, the most
heterogeneous regions were not those with the strongest effects.
Network- and region-based results: effects of painful stimulation. Activation for painful stimulation compared to baseline
(averaged across placebo and control conditions) showed activation of multiple expected cortical and subcortical regions
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Fig. 2 Placebo-induced changes in pain-related activity. a Areas of statistically signiﬁcant placebo treatment effect, assuming random study-effect,
thresholded according to z-tests (uncorrected for multiple comparisons, two-sided p < 0.01, red and blue) and thresholded according to pTFCE-enhanced
permutation test (controlled for FWER, two-sided p < 0.05, light blue, activity increases did not reach statistical signiﬁcance); b unthresholded standardized
effect size g of placebo treatment effect (range: [−0.19, 0.17]); c between-study heterogeneity τ (range: [0, 0.43]) with permutation test results
(controlled for FWER, one-sided, p < 0.05, green); τ is plotted as τ2 to emphasize regions of high heterogeneity. d signiﬁcant placebo-effects assuming ﬁxed
study-effect (range: [−0.22, 0.22]) thresholded according to z-tests (uncorrected for multiple comparisons, two-sided p < 0.01, red and blue) and
thresholded according to pTFCE-enhanced permutation test (controlled for FWER, two-sided p < 0.05, light blue and gold); all: n = 543 to 603 individuals
from 17 to 20 independent studies per voxel. b, c, and d are shown with a contour of FWER-corrected permutation test results for pain > baseline, as shown
in Fig. 1a. Small FWER-corrected clusters are zoomed in insets. Three-dimensional coronal slices are equidistantly distributed from y = 60 to −68 mm.
Axial slices range equidistantly from z = −22 to 42 mm. Custom coordinates for sagittal slices are displayed in mm and were chosen to highlight important
areas of activation. Source data (results as 3d-volumes) are provided at https://osf.io/n9mb3/.

(Fig. 4, Column 2). These included activation in the ventral
attention network (which encompasses the insulae), the frontoparietal network14, and the somatomotor network. Positive
associations were also found in all insular sub-regions and most
thalamic nuclei, including the intralaminar nuclei targeted by
ascending nociceptive pathways, the mediodorsal ‘limbic association’ nucleus, and the ventro-basal complex, including the
ventro-posterior lateral (VPL) nucleus15. A tendency towards
negative associations was found for the lateral geniculate, medial
geniculate, and pulvinar nuclei, which are known for their predominantly visual and auditory roles15.
4

Network- and region-based results: effect of placebo treatment.
Network similarity analysis indicated that placebo treatment
reduced activity in the ventral attention and the somatomotor
networks14; (Fig. 4, Column 3) which includes the mid-cingulate
cortex (localized particularly to area 24pr in ref. 16). In the insula,
placebo reduced activity in bilateral middle short gyrus and right
posterior short gyrus, corresponding to the dorsal anterior/midinsula, as well as a trend towards reduced activity in the right
anterior long gyrus (posterior insula, contralateral to stimulation
in most studies). Thalamic nuclei showed tendencies towards
placebo-induced decreases in areas strongly activated in pain. The
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Fig. 3 Correlations of behavioral placebo analgesia and changes in pain-related brain activity. a Whole-brain areas of statistically signiﬁcant correlation
(Pearson’s r) between behavioral placebo analgesia (paincontrol − painplacebo) and placebo-related activity changes (painplacebo − paincontrol), thresholded
according to z-tests (uncorrected for multiple comparisons, two-sided p < 0.01, red and blue), and thresholded according to pTFCE-enhanced permutation
test (controlled for FWER, two-sided p < 0.05, light blue, increased correlations did not reach corrected statistical signiﬁcance); b unthresholded Pearson’s
r, range: [−0.26; 0.17]; c between-study heterogeneity τ (range: [0, 0.32]) for the same relationship (permutation test controlled for FWER, one-sided p <
0.05, indicated no statistically signiﬁcant voxels); τ is plotted as τ2 to emphasize regions of high heterogeneity. all: n = 384–460 individuals from 15 to 18
independent studies per voxel. a, b, and c are shown with a contour of FWER-corrected permutation test results for pain > baseline, as shown in Fig. 1a.
Correlations were computed across individual participants in the full sample, excluding between-group studies (where individual estimates of behavioral
placebo analgesia are not possible). On panels a and b, red-yellow and blue-light blue shades denote increased and decreased activity associated with
larger placebo analgesia, respectively. Three-dimensional coronal slices are equidistantly distributed from y = 60 to −68 mm. Axial slices range
equidistantly from z = −22 to 42 mm. Custom coordinates for sagittal slices are displayed in mm. Source data (results as 3d-volumes) are provided at
https://osf.io/n9mb3/.

strongest decreases were found in the VPL, a primary target of the
spinothalamic tract, and the habenula. Observed placebo effects
in other regions tended to be smaller.

Network- and region-based results: correlations with placebo
analgesia. As with the main effects of placebo vs. control, network similarity-based analysis of regions correlated with placebo
analgesia indicated that activity in the ventral attention and
somatomotor networks was negatively correlated with behavioral
placebo responses (Fig. 4), i.e., strong placebo responders showed
larger deactivation with placebo treatment. Within the right
insula, several regions tended towards negative correlations with
placebo responses, especially the anterior long gyrus (posterior
insula), middle short gyrus (dorsal anterior/mid insula), and
anterior inferior cortex (ventral insula). In the thalamus, stronger
placebo analgesia was correlated with reductions in multiple
thalamic regions, including all seven regions that responded
strongly to pain in this sample (intralaminar, ventrolateral, ventral anterior, ventromedial, mediodorsal, antero-medial, and
anterio-ventral nuclear groups), and thalamic targets of the spinothalamic tract (ventro-posterior-lateral [VPL] and -medial
[VPM]).

Discussion
In this collaborative effort, we performed a comprehensive, largescale (N = 603) participant-level voxel-based neuroimaging metaanalysis of placebo analgesia, involving the majority of eligible
experimental neuroimaging studies. Our results provide a reliable,
aggregated view of the size, localization, signiﬁcance, and heterogeneity of placebo-effects on pain-induced brain activity. In a
previous paper, we focused on the question of whether placebo
analgesia involves changes in the neurologic pain signature
(NPS)17, a machine-learning based weighted, multi-voxel summary metric (covering about 10% of the brain), that can be
interpreted as a neuromarker of nociceptive pain. This previous
study revealed that behavioral placebo analgesia was associated
with signiﬁcant but small effects in the NPS, pointing to the
relevance of other brain areas and networks. Accordingly, characterizing this potentially broader set of changes was the key
focus of this voxel-wise whole-brain investigation (for a comparison with regions involved in the NPS, see Supplementary
Fig. 13). The present results corroborated previous ﬁndings of
increases in frontal-parietal regions and reductions in the insula.
In addition, they revealed new effects systematically missed
in previous smaller-scale analyses, including reductions in
the habenula, speciﬁc parts of the thalamus (particularly VPL, a
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Fig. 4 Similarity-based analysis of brain activity in functional cortical networks, insula, and thalamus. Column 1 (header): Depiction of atlases: Row 1:
whole-brain cortical networks of functional connectivity14, Row 2: insular sub-regions66 Row 3: thalamic nuclei67. See Supplementary Fig. 14 for further
details. Column 2: Mean (±SEM) cosine similarity (c) of pain-related activity, n = 603 from 20 independent studies; Column 3: Mean (±SEM) cosine
similarity (c) of placebo-induced changes in pain-related activity (Column 2); all: n = 603 from 20 independent studies. Column 4: Correlation (Pearson’s r
± SEM) between behavioral placebo response and cosine similarity estimates of placebo-related activity; n = 460 from 18 independent studies. In Columns
2 and 3, red and blue colors denote increased and decreased pain-related activity, respectively. In Column 4 red and blue shades denote increased and
decreased activity associated with larger placebo analgesia, respectively. Asterisks (*) denote signiﬁcant differences from zero, according to two-sided ttests (p < 0.05, uncorrected for multiple comparisons). Source data (results as 3d-volumes) are provided at https://osf.io/n9mb3/. Hythal Hypothalamus,
Hb Habenular, AV anterior ventral, AM anterior medial, MD mediodorsal, VM ventral medial, VA ventral anterior, LP lateral posterior, VL ventral lateral, LD
lateral dorsal, Intralam intralaminary, VPM ventral posterior medial, VPL ventral posterior lateral, MGN Medial Geniculate Nucleus, LGN Lateral Geniculate
Nucleus, Pulv Pulvinar.

nociceptive nucleus), and the cerebellum, promising new targets
in explaining placebo analgesia.
Here, we discuss our results in correspondence to two key open
questions: (i) how strongly do placebo treatments affect the same
systems involved in nociception and pain generation (as indicated
by the contrast control > placebo); and (ii) which systems are
engaged by placebo treatments (as indicated by the contrast
placebo > control) and may therefore reﬂect top-down modulatory mechanisms.

6

Our study-as-random-effect results provide strong evidence for
placebo-associated reductions of pain-related activity in some
brain areas linked to nociception and pain and indicate that these
are generalizable across experimental paradigms. We also provide
strong evidence that the degree to which pain-related activity is
reduced in these brain areas correlates with the magnitude of
behavioral hypoalgesia across individuals.
Speciﬁcally, the placebo-associated decrease and its correlation
with behavioral pain ratings were most prominent in regions
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located within the ventral attention and the somatomotor cortical
networks, including the anterior insula and targets of the spinothalamic tract18, including the thalamic VPL complex the
posterior insula and, moreover, in the habenula (Figs. 2b and 3b;
Fig. 4, Column 3 and 4). Correlations were additionally pronounced in both lateral (VL and VPM/VPL) and medial (intralaminar and MD) thalamic nuclei (Fig. 4). These regions are
targets of ascending nociceptive systems and, as expected, were
also strongly engaged during painful stimulation. In summary,
placebo-associated down-regulation seems to affect thalamocortical pathways related to nociception and pain13,19, particularly in
strong placebo responders. The relatively low between-study
heterogeneity in these regions indicates that variability in
placebo-related reductions is primarily a function of the individual responder rather than the paradigm used.
These ﬁndings complement previous ﬁndings of small but
statistically signiﬁcant placebo-induced reductions in the NPS7.
In this previous study, NPS reductions also correlated with the
magnitude of placebo analgesia. Here, ﬁndings of VPL reductions
with placebo and widespread correlations between analgesia and
correlations in broadly pain-related systems support the conclusion that alterations in nociception and pain construction are an
important element of placebo analgesia. The small effect sizes
however indicate that nociceptive changes are unlikely to be a
complete explanation. The strengths of the previous NPS ﬁndings
were that the neuromarker was identiﬁed independently from the
present sample and validated in over 40 published cohorts to
date. However, limitations were that (1) the NPS may not perfectly characterize nociceptive processing in this sample, and
some nociceptive pain-related effects may be missed; (2) it cannot
provide a broad view of effects across the brain, including areas
like the habenula and many cortical areas; and (3) it tests a distributed pattern response and is not suited to identify placebo
effects in VPL (or any other region) in particular. The present
ﬁndings of effects in speciﬁc thalamic and other regions are
complementary and important, in that they provide a region-level
inference about effects in neuroanatomically deﬁned nociceptive
pathways. Thus, overall, we believe that placebo effects affect the
circuitry involved in pain generation to some degree, in a manner
that varies across individuals more than across studies in the
present dataset, but also includes other brain effects beyond
nociception that may be important for the emotions, decisionmaking, and behaviors surrounding pain.
Placebo-related decreases were not restricted to pathways
associated with nociception. Brain regions traditionally linked to
self-regulation and high-level action selection, particularly the
SMA20–25 also showed reduced activity during placebo analgesia,
particularly in strong placebo responders (Figs. 2 and 3). Thus, it
is possible that some of these effects reﬂect shifts in motivation
and decision-making in the context of pain. These ﬁndings
extend previous meta-analyses, which all highlighted deactivations in the mid-cingulate, but not the SMA or pre-motor
areas4–6. In addition to action planning and self-regulation, they
may be related to other cognitive operations related to evaluating
pain under placebo treatment, including error monitoring, prediction errors, and sequence processing20,26.
One of the strongest effects was found in the left putamen,
which de-activated with placebo in proportion to analgesia. This
is in line with multiple studies reporting correlations between
placebo analgesia and both fronto-parietal and limbic frontostriatal pathways8 and might be related to the (prefrontal) suppression of striatal prediction errors or other aversive circuits27.
Interestingly, each of the main analyses revealed prominent
placebo-related reductions in cerebellar regions. While this in line
with some previous ﬁndings (e.g.12), cerebellar effects were not
reported in previous meta-analyses of placebo analgesia, possibly
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due to insufﬁcient cerebellar coverage across studies. Here, the
dorsomedial cerebellum showed a proﬁle of responses to painful
events, reductions with placebo, and correlations with the magnitude of placebo analgesia. Some cerebellar regions have been
linked to pain, and others to other cognitive, affective, and motor
processes28,29 and patients with cerebellar infarctions show
reduced placebo analgesia30. Cerebellar reductions and correlations are centered in vermis areas V and (to a lesser degree)
II31–33, which are associated with somatomotor and limbic cortical networks, respectively. Thus, the best interpretation of cerebellar effects here is that they are related partly, but not
exclusively, to somatomotor networks and pain. Placebo
hypoalgesia-related activity changes in the VL nucleus, a target of
cerebellothalamic tract15, also suggest that fronto-cerebellar
connectivity may pose a promising novel target for future indepth studies on the mechanisms of placebo analgesia.
In contrast to these placebo-related deactivations, some regions
displayed increased pain-related activity as an effect of placebo
treatment, which is often interpreted as participating in the
construction of top-down representations of context (including
beliefs and expectations). These regions tend to be localized in the
frontoparietal network (FPN). These increases were statistically
signiﬁcant only in the ﬁxed effect analysis and involved the right
DLPFC (with subthreshold activation on the left side), as well as
the bilateral intraparietal sulcus. While the ﬁxed-effect analysis
provides limited generalizability, this result is very much in line
with previous neuroimaging studies highlighting the importance
of the DLPFC in initiating and maintaining the top-down effect
of treatment expectation on nociceptive processing and pain. E.g.
activity in the DLPFC precedes and scales with activity changes in
downstream pain modulatory areas and prevents the extinction of
once learned placebo analgesia27. Moreover, transient inhibition
of the DLPFC using transcranial magnetic stimulation led to
reduced placebo analgesia34.
The lack of FWER-corrected increases might be attributed to
the reduced power in the study-as-random-effect analysis, which
is very conservative. However, the heterogeneity analysis indicates
that the between-study variance is signiﬁcantly higher than
expected in key fronto-parietal areas (Fig. 2c). This suggests that,
in contrast to the consistent placebo-induced decreases across
studies, placebo-related increases in brain activity are more heterogenous across placebo induction techniques. For instance,
signiﬁcant heterogeneity in the DLPFC and perigenual ACC
might reﬂect the differing engagement of descending pain regulatory mechanisms across studies, although these regions are
clearly not exclusively associated with pain modulation (e.g. see
ref. 35).
Between-study heterogeneity was statistically signiﬁcant
throughout the frontal lobe (Fig. 2c), which may reﬂect interstudy variation in participants’ appraisal of the context and
internal responses, e.g., expectations36. The degree to which
prefrontal systems are required for analgesia may vary. For
example, in ref. 37, placebo analgesia was predicted by frontoparietal activity in regions associated with emotion regulation but
not working memory. Emotion regulation, in particular reappraisal strategies involving self-generated positive contexts for
experiences, appears to involve fronto-parietal networks in
reducing negative affect. Other recent studies have also found
correlations between placebo analgesia and DLPFC connectivity38,39 (e.g., with the nucleus accumbens40) and opioid
binding in prefrontal cortex41,42. By contrast, other studies have
found that mindfulness practice can reduce pain without frontoparietal activation or appreciable deactivation in spinothalamic
targets43. These strategies focus on acceptance without judgment
rather than active re-contextualization, which may be another
important component of placebo analgesia.
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In sum, placebo analgesia may involve multiple alterations in
appraisal systems, reﬂecting multiple underlying mechanisms44.
Our results suggest that placebo effects are not restricted solely to
either sensory/nociceptive or cognitive/affective processes, but
likely involve a combination of mechanisms that may differ
depending on the paradigm and other individual factors.
Understanding the neural and neurochemical pathways underlying this variability will pave the way to systematically utilize/
modulate placebo responses in a context-, patient-, and diseasespeciﬁc manner. Fostering the therapeutic processes underlying
placebo effects in clinical settings promises to boost the efﬁcacy
(and tolerability) of analgesic drug treatments. Likewise, controlling and homogenizing placebo responses during drug
development can enhance the assay sensitivity in clinical trials.
Finally, biomarkers based on the types of brain alterations we
identify here, and reported in other studies38,45, may help to
dissect placebo from analgesic drug responses in pre-clinical
trials.
The present ﬁndings must be interpreted in the light of several
limitations. First, as our ﬁndings are based on experimental placebo interventions in healthy volunteers, they may not generalize
to clinical settings. Second, the present study covered a wide
range of experimental placebo paradigms and conditions. This is
favorable in terms of establishing the broad generalizability of
results, but it also means that ﬁndings have to generalize over
many sources of variation: Paradigm, population/sample, scanner, and choice of analysis methods. Effect size estimates are thus
likely overly conservative compared with what may be possible as
analysis methods continue to become standardized and methodological advances reduce inter-subject and inter-study variability. Further, the fact that this meta-analysis was based on
participant-level statistical summary images from variety of different pre-processing pipelines (s. Supplementary Table 5) likely
had a negative impact on spatial brain mapping accuracy, in
particular since different software packages46 (and therefore
MNI-templates47) and different spatial smoothing kernels were
used. This study therefore trades off spatial precision for generalizability across scanners, populations, pipelines, and paradigms. Finally, some brain regions, notably the orbitofrontal
cortex (including the vmPFC), the inferior cerebellum and the
top-most part of the brain were not fully covered (Supplementary
Figs. 2 and 3) and placebo-related activation changes in these
regions could not be assessed and may be missed.
In this systematic meta-analysis of individual participant data,
we show that placebo treatments induce small, yet robust, inhibitory effects in large parts of the brain. These involve selected
regions within the ventral attention and somatomotor networks,
including targets of spinothalamic-afferents strongly linked to
nociception, and are consistent across studies. Further, our study
corroborates the relevance of placebo-related activity in frontoparietal areas; however, the degree and relevance of frontoparietal activity show large between-study heterogeneity. Our
results suggest, that placebo is neither restricted to sensory/
nociceptive nor to selective cognitive/affective processes but likely
involves a combination of mechanisms that may differ depending
on the paradigm and other individual factors.
Methods
The present study is a systematic meta-analysis of participant-level data across 20
published studies. A previous paper on this dataset7 tested placebo effects on a
single, a priori pain-related measure (the neurologic pain signature17). Here, we
used the same data set to map placebo responses across the brain. In contrast to the
previous analysis, which was restricted to the NPS as a neuromarker of nociceptive
processing, this manuscript now focuses on voxel-wise brain-activity. This allows
us to investigate placebo effects on individual regions and the distribution of effects
across the brain, including in regions associated with affective and cognitive processes beyond nociception.
8

Data acquisition. As previously described7, we performed a systematic literature
search to identify experimental functional magnetic resonance imaging (fMRI)
investigations of placebo analgesia (see Supplementary Fig. 1, Supplementary
Table 1, and ref. 7 for details). Criteria for study eligibility were: (a) published in
peer-reviewed journal in the English language; (b) original investigation; (c) human
participants; (d) functional neuroimaging of the brain during evoked pain; (e) pain
delivered under matched placebo and control conditions. Deﬁnitions of placebo and
control conditions (see Supplementary Methods and Results) were identical to our
previous meta-analysis7. Investigators of eligible studies were contacted and invited
to share data. We collected single-participant, ﬁrst-level, whole-brain standardspace summary images of pain response (statistical parametric maps) from the
original analyses, as published, as well as corresponding pain ratings, experimental
design parameters, and demographic data (Supplementary Tables 2–5).
Outcome deﬁnition and comparisons. The main outcome was pain-related
change in fMRI signal (i.e., blood oxygen level-dependent signal, perfusion changes), i.e., the effect of painful stimulation compared to baseline, as estimated in the
original analyses (i.e., beta or contrast images). Based on this outcome, we performed three comparisons: (i) main effect of pain vs baseline, averaging placebo
and control conditions; (ii) pain-related activity acquired under matched placebo
and control conditions (placebo–control); and (iii), for studies that manipulated
placebo vs. control within-subject, correlations across individuals between the
effect of placebo treatment on brain activity and behavioral placebo analgesia (i.e.,
[placebo–control] in pain ratings).
Non-painful or mildly painful12,48–52 stimulus conditions were excluded. For
studies that involved left- and right-lateralized stimulation53, strong and weak
placebo conditions54,55, or early- and late heat-pain periods55–57 maps were
averaged on subject level, as in the previous analysis7 (see Supplementary Table 6
for details). The main effect of pain vs baseline was averaged across placebo and
control conditions (instead of just using no-placebo conditions) because for some
studies48 only pooled estimates of the main effect of pain were available (see
Supplementary Methods and Results for details).
Analysis. We applied the Cochrane risk of bias tool58 to assess the risk-of-bias of
included studies. (Supplementary Methods and Results and Supplementary
Table 7).
Images underwent systematic quality control, as described previously7 (see
Supplementary Methods and Results for details). Voxels missing in >10% of
participants (n > 60) or outside of the MNI152 brain-template (as implemented in
SPM1259, probability of brain tissue <50%) were excluded from analysis.
Outcome assessment was performed in a mass-univariate fashion, separately for
each brain voxel. To account for between-study differences in the scaling of pain
reports and imaging data, we used standardized effect sizes rather than the raw
values. Standardization of effect sizes (mean response to pain and its difference
between placebo and control conditions) was based on the between-subject-level
standard deviation of pain-related brain activity, separately for each study, by using
Hedges’ g (Hedges’ grm for within-subject studies60), a small-sample bias-corrected
version of Cohen’s d, commonly used in meta-analysis58. Furthermore, we used
Pearson’s r to assess correlations between placebo analgesia and its effects on brain
activity in studies with a within-subject design (18 studies, 460 participants). Studylevel effect size estimates were summarized using the generic inverse-variance
(GIV) weighting method, accounting for study as a random effect61,62. Pearson’s r
was transformed to Fisher’s Z for across-study averages and tests of statistical
inference. Between-study heterogeneity in effect size was estimated using the τstatistic, which represents the study-level standard deviation of effect sizes62. Effect
size summaries and standard errors were used to calculate z-62 and pseudo-zscores63, the latter was based on smoothened (4 * 4 * 4 mm full-width-halfmaximum Gaussian kernel) instead of raw standard errors, as described in ref. 63.
Voxel-wise p-values were obtained by performing a non-parametric permutationtest of the pseudo-z statistic63, correcting for multiple comparisons at Family Wise
Error (FWER) level, according to the maximum-z method63. Permutation testing
was performed at 1500 random permutations, small (p < 0.01) p-values were
approximated by tail-ﬁtting a generalized Pareto distribution64. To perform a
robust enhancement of spatially extended activations and, at the same time,
allowing for simple z-score-based thresholding, we performed probabilistic
threshold-free cluster enhancement (pTFCE)65. Both enhanced and unenhanced
z-score maps were thresholded at an FWER-corrected alpha level of p < 0.05. For
visualization, unenhanced z-score maps were thresholded at an uncorrected alpha
level of p < 0.05. All p-values presented are two-tailed.
To aid the interpretation of results, we utilized cosine similarity in an
exploratory analysis comparing the participant-level contrast maps with brainparcellation atlases representing (i) canonical large-scale functional connectivity
networks14 (resting-state), as well as (ii) insular sub-regions (anatomy based)66,
and (iii) thalamic nuclei (anatomy based)67, i.e., the most prominent brain regions
involved in pain processing13. Note that the large-scale functional connectivity
networks are based on resting-state data, thus reverse-inference and direct
associations to task-based activity should be performed carefully. On the other
hand, large-scale resting-state networks have de-facto evolved as standard means
for brain-wide localization68. Accordingly, we use these canonical networks solely
for localization purposes. Obtained participant-level cosine similarity values were

NATURE COMMUNICATIONS | (2021)12:1391 | https://doi.org/10.1038/s41467-021-21179-3 | www.nature.com/naturecommunications

NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-21179-3

summarized using the GIV method, with statistics based on t-tests across studies,
treating study as a random effect. No correction for multiple comparisons was
performed for the atlas-based analyses due to their exploratory nature. Cosine
similarity is equivalent to Pearson’s correlation except for mean-centering, so it
remains sensitive to the overall level of activation across the brain and thus reﬂects
absolute normalized activity levels in the regions/networks tested rather than
relative activity across regions.
All analyses were performed with MATLAB 2016b, SPM12, the CANlab Core
Tools neuroimaging analysis toolbox (https://github.com/canlab/CanlabCore), and
custom functions implementing the GIV method. Further analysis details are
provided in the Supplementary Methods and Results.
MRIcroGL (v28.5.2017) was used to create illustrations of statistical parametric
maps. All neuroimages shown follow the neurological convention (left side
corresponds to left hemisphere in coronal- and axial-sections). Effect sizes are
interpreted as small, moderate, and large according to the recommendations by
Cohen69. All result maps from this meta-analysis are available for download as 3d
NIFTI images at https://osf.io/n9mb3/.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.

Data availability
Results as 3d-volumes are provided at https://osf.io/n9mb3/. Participant-level source data
are available from the authors upon reasonable request and with permission of the
Placebo Imaging Consortium.

Code availability
The full analysis code is available at https://github.com/mzunhammer/
PlaceboImagingMetaAnalysis.
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